Aurobindo Pharma’s Subsidiary CuraTeQ Secures UK Approval for Bevacizumab Biosimilar

SCG Cell Therapy Partners with A*STAR BTI and NATi to Advance RNA-Based Therapeutics

Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Home
/
update
/
details

TVM Capital Healthcare Invests in Human Longevity Inc. to Drive Global Expansion of Precision Medicine

NextEdge Admin

18 Sep 2024

2 min 56 sec

TVM Capital Healthcare, a global healthcare expansion firm, has made an equity investment in Human Longevity Inc. (HLI), a San Francisco-based leader in precision medicine and longevity science. Founded by Dr. J. Craig Venter in 2013, HLI aims to extend healthy life spans through its groundbreaking work in genomics, advanced imaging, and AI-driven health risk platforms. The company provides pre-symptomatic diagnoses and highly personalized treatments designed to prevent avoidable diseases, positioning it as a key player in the rapidly growing longevity medicine field.

This investment, provided through the Saudi Arabia-focused TVM Healthcare Afiyah Fund LP, will support HLI’s expansion in the U.S. and drive its entry into key international markets, including Saudi Arabia and Southeast Asia. Saudi Arabia is particularly receptive to innovative healthcare models like HLI’s, with government-backed initiatives such as the Saudi Human Genome Program and the Hevolution Foundation. The latter, based in Riyadh, is a global non-profit organization focused on investing in life science companies and research projects in the longevity field.

Dr. Venter, Co-Founder and Chief Scientific Advisor of HLI, highlighted the importance of staying ahead of aging and illness, stating that HLI’s platform could save millions of lives and significantly lower healthcare costs in the future. The investment from TVM Capital Healthcare will enable the company to strengthen its global leadership in longevity medicine while expanding into markets that recognize the potential of precision medicine and preventive healthcare.

Dr. Helmut M. Schuehsler, Chairman and CEO of TVM Capital Healthcare, emphasized that this investment is part of a broader shift toward "healthcare of the future," which focuses on precision medicine, personalized care, and prevention. Dr. Ghida Harfouche, Partner at TVM Capital, praised HLI’s innovative science and expressed confidence in its ability to democratize healthy longevity globally while revolutionizing preventive care.